Literature DB >> 21216016

Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism.

Barbara Rossi1, Elena Zenaro, Stefano Angiari, Linda Ottoboni, Simona Bach, Laura Piccio, Enrica C Pietronigro, Elio Scarpini, Mariella Fusco, Alberta Leon, Gabriela Constantin.   

Abstract

It is well known that the cannabinoid system has a significant role in the regulation of the immune responses. Cannabinoid receptors CB1 and CB2 are expressed on T lymphocytes and mediate the immunomodulatory effects of cannabinoids on T cell functions. Here we show that the treatment of proteolipid protein (PLP)139-151-specific T cells with SR141716A, a CB1 inverse agonist and prototype of the diarylpyrazoles series, induced a strong inhibition of firm adhesion in inflamed brain venules in intravital microscopy experiments. In contrast, SR144528, a potent CB2 inverse agonist, had no significant effect on both rolling and arrest of activated T cells. In addition, two analogs of SR141716A and CB1 inverse agonists, AM251 and AM281 inhibited encephalitogenic T cell adhesion suggesting that selective CB1 inverse agonism interfere with lymphocyte trafficking in the CNS. Flow cytometry experiments showed that CB1 inverse agonists have no effect on adhesion molecule expression suggesting that CB1 blockade interferes with signal transduction pathways controlling T cell adhesion in inflamed brain venules. In addition, integrin clustering was not altered after treatment with CB1 inverse agonists suggesting that adhesion blockade is not due to the modulation of integrin valency. Notably, the inhibitory effect exerted by AM251 and AM281 on the adhesive interactions was completely reverted in the presence of protein kinase A (PKA) inhibitor H89, suggesting that cAMP and PKA activation play a key role in the adhesion blockade mediated by CB1 inverse agonists. To further strengthen these results and unveil a previously unknown inhibitory role of cAMP on activated T cell adhesion in vivo in the context of CNS inflammation, we showed that intracellular increase of cAMP induced by treatment with Bt2cAMP, a permeable analog of cAMP, and phosphodiesterase (PDE) inhibitor theophylline efficiently blocked the arrest of encephalitogenic T cells in inflamed brain venules. Our data show that modulation of CB1 function has anti-inflammatory effects and suggests that inverse agonism of CB1 block signal transduction mechanisms controlling encephalitogenic T cells adhesion in inflamed brain venules by a PKA-dependent mechanism.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216016     DOI: 10.1016/j.jneuroim.2010.12.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Cannabinoid receptors in mantle cell lymphoma.

Authors:  Agata M Wasik; Birgitta Sander
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model.

Authors:  Caroline Vandeputte; Cindy Casteels; Tom Struys; Michel Koole; Daisy van Veghel; Nele Evens; Anneleen Gerits; Tom Dresselaers; Ivo Lambrichts; Uwe Himmelreich; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-16       Impact factor: 9.236

Review 3.  Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses.

Authors:  Valerio Chiurchiù; Alessandro Leuti; Mauro Maccarrone
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-20       Impact factor: 4.147

4.  Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.

Authors:  Agata M Wasik; Lina Nygren; Stefan Almestrand; Fang Zong; Jenny Flygare; Stefanie Baumgartner Wennerholm; Leonie Saft; Patrik Andersson; Eva Kimby; Björn E Wahlin; Birger Christensson; Birgitta Sander
Journal:  Oncoscience       Date:  2014-09-04

Review 5.  Update on the role of cannabinoid receptors after ischemic stroke.

Authors:  Luciano S A Capettini; Silvia Q Savergnini; Rafaela F da Silva; Nikos Stergiopulos; Robson A S Santos; François Mach; Fabrizio Montecucco
Journal:  Mediators Inflamm       Date:  2012-04-05       Impact factor: 4.711

Review 6.  Real-Time Imaging of Immune Modulation by Cannabinoids Using Intravital Fluorescence Microscopy.

Authors:  Juan Zhou; Kiyana Kamali; J Daniel Lafreniere; Christian Lehmann
Journal:  Cannabis Cannabinoid Res       Date:  2021-05-27

Review 7.  Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis.

Authors:  Torsten Lowin; Rainer H Straub
Journal:  Arthritis Res Ther       Date:  2015-09-06       Impact factor: 5.156

Review 8.  Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.

Authors:  José Antonio Estrada; Irazú Contreras
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.